43 Pharmas Apply To Make Generics Of Off-Patent Plavix In China
This article was originally published in PharmAsia News
China’s State FDA received applications from 43 Chinese drug companies to manufacture generics of Sanofi’s $10-billion anti-clotting drug Plavix, whose patent expired in May.
You may also be interested in...
Crystal ball gazing is a tricky, sometimes futile, endeavor. No one knows what the future holds, but there are consistent scenarios emerging that are being debated by industry leaders as they try to foretell and outsmart key market catalysts expected to ripple across the biopharma sector in 2020. With insights from executives, investors and consultancies, as well as our own experts, In Vivo can paint a picture of biopharma wins and woes expected in the new year and new decade.
Janssen’s hemato-oncology success rolls on with impressive new overall survival data
Lannett’s Phase I trial for biosimilar insulin glargine has met “all primary endpoints,” the company has announced. The rival to Sanofi’s Lantus is being developed by Lannett with partner HEC through a deal for which financial details have just been revealed.